New Danish company found its main asset and initiates clinical trials in 2020

Danish Antag Therapeutics has chosen its main asset and is now preparing for pre-clinical and later clinical trials. At the same time, one more experienced biotech offier enters the board of directors.

Photo: Giulia Mangione

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles